BB Biotech AGBBAGF -29.53%15 EV-to-FCF is 5.57 as of Jun. 27, 2026, which is 59% below its 10-year median of 13.66. GuruFocus rates BBAGF with a GF Score™ of 15/100. The stock has 3 warning signs investors should review. Among 333 Biotechnology companies, BB Biotech AG ranks better than 64.56% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BB Biotech AG's Enterprise Value is $2,791 Mil.
BB Biotech AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $501 Mil. Therefore, BB Biotech AG's EV-to-FCF for today is 5.57.
The historical rank and industry rank for BB Biotech AG's EV-to-FCF or its related term are showing as below:
BBAGF'
s EV-to-FCF Range Over the Past 10 Years
Min: -131.67 Med: 13.66 Max: 1496.78
Current: 5.48
During the past 13 years, the highest EV-to-FCF of BB Biotech AG was 1496.78. The lowest was -131.67. And the median was 13.66.
BBAGF's EV-to-FCF is ranked better than 64.56% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs BBAGF: 5.48
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BB Biotech AG's PE Ratio (TTM) for today is calculated as:
BB Biotech AG's share price for today is $76.05789.
BB Biotech AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.297.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BB Biotech AG EV-to-FCF Related Terms
BB Biotech AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BB Biotech AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BB Biotech AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's EV-to-FCF falls into.
BB Biotech AG's current Enterprise Value is $2,791 Mil.
BB Biotech AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $501 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BB Biotech AG (BBAGF) has a EV-to-FCF of 5.57 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BB Biotech AG and its competitors. This is 59% below median its historical median of 13.66. According to the industry distribution chart, BB Biotech AG ranks #118 out of 333 companies in the Biotechnology industry, placing it in the top 35.4%.
Is BB Biotech AG's EV-to-FCF too high?
BB Biotech AG's current EV-to-FCF of 5.57 is 59% below median its 10-year median of 13.66. The Biotechnology industry median EV-to-FCF is 14.65. BB Biotech AG's value of 5.57 is 62% below this industry median. Based on the distribution chart, BB Biotech AG ranks #118 out of 333 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BB Biotech AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BB Biotech AG ranks #118 out of 333 companies for EV-to-FCF. This puts BB Biotech AG in the upper half of its industry. The industry median EV-to-FCF is 14.65. BB Biotech AG's value of 5.57 is 62% below this benchmark. While the company's 10-year median is 13.66 vs. the industry median of 14.65, BB Biotech AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BB Biotech AG's current EV-to-FCF of 5.57 is 62% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BB Biotech AG and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BB Biotech AG's current EV-to-FCF is 5.57, which is 59% below median its own 10-year median of 13.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (BBAGF) has a current EV-to-FCF of 5.57. The current EV-to-FCF is 5.57, which is 59% below median its 10-year median of 13.66 and 62% below the Biotechnology industry median of 14.65. BB Biotech AG's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BB Biotech AG (BBAGF), the current EV-to-FCF is 5.57 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
15GF Score
Get the complete analysis for BBAGF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBAGF has been successfully added to your 
